Fibromyalgia: Mechanisms, current treatment and animal models

Current Pharmaceutical Biotechnology

Volumn 12, Issue 10, 2011, Pages 1613-1626

  Brederson, Jill Desiree ^a   Jarvis, Michael F ^a   Honore, Prisca ^a   Surowy, Carol S ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Central dysfunction; Chronic widespread pain; Etiology; Musculoskeletal; Pathophysiology; Pharmacologic therapy; Potential models

Indexed keywords

ADRENERGIC RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; AMITRIPTYLINE; ARMODAFINIL; BIOGENIC AMINE; CANNABINOID DERIVATIVE; CATECHOL METHYLTRANSFERASE; CYCLOBENZAPRINE; DESVENLAFAXINE; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR 4; DOPAMINE TRANSPORTER; DOPAMINE TRANSPORTER 1; DULOXETINE; FLUOXETINE; KETAMINE; MILNACIPRAN; OPIATE RECEPTOR; OXYBATE SODIUM; PLACEBO; PRAMIPEXOLE; PREGABALIN; S ADENOSYLMETHIONINE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRAMADOL; TROPISETRON; UNCLASSIFIED DRUG;

ACOUSTIC STRESS; ALLODYNIA; ANALGESIC ACTIVITY; AREA UNDER THE CURVE; BLOOD OXYGENATION; BLURRED VISION; BODY WEIGHT; CATAPLEXY; CENTRAL NERVOUS SYSTEM; CHRONIC PAIN; COLD STRESS; CONSTIPATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; FIBROMYALGIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEART PALPITATION; HUMAN; HYPERALGESIA; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MONOAMINE METABOLISM; NARCOLEPSY; NAUSEA; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OPTIMAL DRUG DOSE; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PARESTHESIA; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATOSENSORY SYSTEM; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA;

ANIMALIA; RODENTIA;

EID: 80053535483     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798357258     Document Type: Review

References (120)

1. Willis, W. D.; Westlund, K. N. Neuroanatomy of the pain system and of the pathways that modulate pain. J. Clin. Neurophysiol., 1997, 14 (1), 2-31.
2. Heinricher, M. M.; Tavares, I.; Leith, J. L.; Lumb, B. M. Descending control of nociception: Specificity, recruitment and plasticity. Brain Res. Rev., 2009, 60 (1), 214-225.
3. Burgess, P. R.; Perl, E. R. Myelinated afferent fibres responding specifically to noxious stimulation of the skin. J. Physiol., 1967, 190 (3), 541-562.
4. Le Bars, D.; Villanueva, L.; Bouhassira, D.; Willer, J. C. Diffuse noxious inhibitory controls (DNIC) in animals and in man. Patol. Fiziol. Eksp. Ter., 1992, (4), 55-65.
5. Campbell, J. N.; Meyer, R. A., Mechanisms of neuropathic pain. Neuron, 2006, 52 (1), 77-92.
6. Treede, R. D.; Meyer, R. A.; Raja, S. N.; Campbell, J. N. Peripheral and central mechanisms of cutaneous hyperalgesia. Prog. Neurobiol., 1992, 38 (4), 397-421.
7. Latremoliere, A.; Woolf, C. J. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J. Pain, 2009, 10 (9), 895-926.
8. Staud, R.; Rodriguez, M. E. Mechanisms of disease: pain in fibromyalgia syndrome. Nat. Clin. Pract. Rheumatol., 2006, 2 (2), 90-98.
9. Nielsen, L. A.; Henriksson, K. G. Pathophysiological mechanisms in chronic musculoskeletal pain (fibromyalgia): the role of central and peripheral sensitization and pain disinhibition. Best Pract. Res. Clin. Rheumatol., 2007, 21 (3), 465-480.
10. Bradley, L. A. Pathophysiologic mechanisms of fibromyalgia and its related disorders. J. Clin. Psychiatry, 2008, 69 (Suppl 2), 6-13.
11. Goldenberg, D. L. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract. Res. Clin. Rheumatol., 2007, 21 (3), 499-511.
12. Sarchielli, P.; Mancini, M. L.; Floridi, A.; Coppola, F.; Rossi, C.; Nardi, K.; Acciarresi, M.; Pini, L. A.; Calabresi, P. Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J. Pain, 2007, 8 (9), 737-745.
13. Wood, P. B.; Schweinhardt, P.; Jaeger, E.; Dagher, A.; Hakyemez, H.; Rabiner, E. A.; Bushnell, M. C.; Chizh, B. A. Fibromyalgia patients show an abnormal dopamine response to pain. Eur. J. Neurosci., 2007, 25 (12), 3576-3582.
14. Yunus, M. B. Role of central sensitization in symptoms beyond muscle pain, and the evaluation of a patient with widespread pain. Best Pract. Res. Clin. Rheumatol., 2007, 21 (3), 481-497.
15. Ablin, J. N.; Cohen, H.; Buskila, D. Mechanisms of Disease: genetics of fibromyalgia. Nat. Clin. Pract. Rheumatol., 2006, 2 (12), 671-678.
16. Buskila, D.; Sarzi-Puttini, P.; Ablin, J. N. The genetics of fibromyalgia syndrome. Pharmacogenomics, 2007, 8 (1), 67-74.
17. Lotsch, J.; Geisslinger, G.; Tegeder, I. Genetic modulation of the pharmacological treatment of pain. Pharmacol. Ther., 2009, 124 (2), 168-184.
18. Sluka, K. A.; Kalra, A.; Moore, S. A. Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia. Muscle Nerve, 2001, 24 (1), 37-46.
19. Khasar, S. G.; Green, P. G.; Levine, J. D. Repeated sound stress enhances inflammatory pain in the rat. Pain, 2005, 116 (1-2), 79-86.
20. Nishiyori, M.; Ueda, H. Prolonged gabapentin analgesia in an experimental mouse model of fibromyalgia. Mol. Pain, 2008, 4, 52.
21. Nagakura, Y.; Oe, T.; Aoki, T.; Matsuoka, N. Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia. Pain, 2009, 146 (1-2), 26-33.
22. Buskila, D.; Sarzi-Puttini, P. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res. Ther., 2006, 8 (5), 218.
23. Buskila, D. Genetics of chronic pain states. Best Pract. Res. Clin. Rheumatol., 2007, 21 (3), 535-547.
24. Heils, A.; Teufel, A.; Petri, S.; Stober, G.; Riederer, P.; Bengel, D.; Lesch, K. P. Allelic variation of human serotonin transporter gene expression. J. Neurochem., 1996, 66 (6), 2621-2624.
25. Ogilvie, A. D.; Russell, M. B.; Dhall, P.; Battersby, S.; Ulrich, V.; Smith, C. A.; Goodwin, G. M.; Harmar, A. J.; Olesen, J. Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. Cephalalgia, 1998, 18 (1), 23-26.
26. Hanna, G. L.; Himle, J. A.; Curtis, G. C.; Koram, D. Q.; Veenstra- VanderWeele, J.; Leventhal, B. L.; Cook, E. H. Jr., Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology, 1998, 18 (2), 102-111.
27. Offenbaecher, M.; Bondy, B.; de Jonge, S.; Glatzeder, K.; Kruger, M.; Schoeps, P.; Ackenheil, M. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum., 1999, 42 (11), 2482-2488.
28. Wood, P. B., Role of central dopamine in pain and analgesia. Expert Rev. Neurother., 2008, 8 (5), 781-797.
29. Potvin, S.; Larouche, A.; Normand, E.; de Souza, J. B.; Gaumond, I.; Grignon, S.; Marchand, S. DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls. J. Pain, 2009, 10 (9), 969-975.
30. Treister, R.; Pud, D.; Ebstein, R. P.; Laiba, E.; Gershon, E.; Haddad, M.; Eisenberg, E. Associations between polymorphisms in do pamine neurotransmitter pathway genes and pain response in healthy humans. Pain 2009, 147 (1-3), 187-193.
31. Cevoli, S.; Mochi, M.; Scapoli, C.; Marzocchi, N.; Pierangeli, G.; Pini, L. A.; Cortelli, P.; Montagna, P. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur. J. Neurol., 2006, 13 (9), 1009-1013.
32. Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 1996, 379 (6566), 606-612.
33. Diatchenko, L.; Nackley, A. G.; Slade, G. D.; Bhalang, K.; Belfer, I.; Max, M. B.; Goldman, D.; Maixner, W. Catechol-Omethyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain, 2006, 125 (3), 216-224.
34. Gursoy, S.; Erdal, E.; Herken, H.; Madenci, E.; Alasehirli, B.; Erdal, N., Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol. Int., 2003, 23 (3), 104-107.
35. Erdal, M. E.; Herken, H.; Yilmaz, M.; Bayazit, Y. A. Significance of the catechol-O-methyltransferase gene polymorphism in migraine. Mol. Brain Res., 2001, 94 193-196.
36. Vargas-Alarcon, G.; Fragoso, J. M.; Cruz-Robles, D.; Vargas, A.; Vargas, A.; Lao-Villadoniga, J. I.; Garcia-Fructuoso, F.; Ramos- Kuri, M.; Hernandez, F.; Springall, R.; Bojalil, R.; Vallejo, M.; Martinez-Lavin, M. Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia. Arthritis Res. Ther., 2007, 9 (5), R110.
37. Vargas-Alarcon, G.; Fragoso, J. M.; Cruz-Robles, D.; Vargas, A.; Martinez, A.; Lao-Villadoniga, J. I.; Garcia-Fructuoso, F.; Vallejo, M.; Martinez-Lavin, M. Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains. Arthritis Rheum., 2009, 60 (7), 2169-2173.
38. Salemi, S.; Aeschlimann, A.; Wollina, U.; Gay, R. E.; Michel, B. A.; Gay, S.; Sprott, H. Up-regulation of delta-opioid receptors and kappa-opioid receptors in the skin of fibromyalgia patients. Arthritis Rheum., 2007, 56 (7), 2464-2466.
39. Salemi, S.; Aeschlimann, A.; Gay, R. E.; Michel, B. A.; Gay, S.; Kaeser, L.; Sprott, H., Expression and localization of opioid receptors in muscle satellite cells: no difference between fibromyalgia patients and healthy subjects. Arthritis Rheum., 2003, 48 (11), 3291-3293.
40. Toth, C.; Rong, L. L.; Yang, C.; Martinez, J.; Song, F.; Ramji, N.; Brussee, V.; Liu, W.; Durand, J.; Nguyen, M. D.; Schmidt, A. M.; Zochodne, D. W. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes, 2008, 57 (4), 1002-1017.
41. Hein, G.; Franke, S. Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology, (Oxford) 2002, 41 (10), 1163-1167.
42. Ruster, M.; Franke, S.; Spath, M.; Pongratz, D. E.; Stein, G.; Hein, G. E. Detection of elevated N epsilon-carboxymethyllysine levels in muscular tissue and in serum of patients with fibromyalgia. Scand J. Rheumatol., 2005, 34 (6), 460-463.
43. Blanco, I.; Janciauskiene, S.; Nita, I.; Fernandez-Bustillo, E.; Carcaba, V.; Gallo, C.; Alvarez-Rico, M.; de Serres, F.; Beridze, N. Low plasma levels of monocyte chemoattractant protein-1 (MCP- 1), tumor necrosis factor-alpha (TNFalpha), and vascular endothelial growth factor (VEGF) in patients with alpha1-antitrypsin deficiency- related fibromyalgia. Clin. Rheumatol., 2010, 29 (2), 189-197.
44. Harris, R. E.; Clauw, D. J.; Scott, D. J.; McLean, S. A.; Gracely, R. H.; Zubieta, J. K. Decreased central mu-opioid receptor availability in fibromyalgia. J. Neurosci., 2007, 27 (37), 10000-10006.
45. Baraniuk, J. N.; Whalen, G.; Cunningham, J.; Clauw, D. J. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord., 2004, 5, 48.
46. Russell, I. J.; Vaeroy, H.; Javors, M.; Nyberg, F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum., 1992, 35 (5), 550-556.
47. Yunus, M. B.; Dailey, J. W.; Aldag, J. C.; Masi, A. T.; Jobe, P. C. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J. Rheumatol., 1992, 19 (1), 90-94.
48. Mountz, J. M.; Bradley, L. A.; Modell, J. G.; Alexander, R. W.; Triana-Alexander, M.; Aaron, L. A.; Stewart, K. E.; Alarcon, G. S.; Mountz, J. D. Fibromyalgia in women. Abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis Rheum., 1995, 38 (7), 926-938.
49. Kwiatek, R.; Barnden, L.; Tedman, R.; Jarrett, R.; Chew, J.; Rowe, C.; Pile, K. Regional cerebral blood flow in fibromyalgia: singlephoton- emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum., 2000, 43 (12), 2823-2833.
50. Lautenbacher, S.; Rollman, G. B. Possible deficiencies of pain modulation in fibromyalgia. Clin. J. Pain, 1997, 13 (3), 189-196.
51. Gracely, R. H.; Petzke, F.; Wolf, J. M.; Clauw, D. J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum., 2002, 46 (5), 1333-1343.
52. Julien, N.; Goffaux, P.; Arsenault, P.; Marchand, S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain, 2005, 114 (1-2), 295-302.
53. de Souza, J. B.; Potvin, S.; Goffaux, P.; Charest, J.; Marchand, S. The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. Clin. J. Pain, 2009, 25 (2), 123-127.
54. Goffaux, P.; de Souza, J. B.; Potvin, S.; Marchand, S. Pain relief through expectation supersedes descending inhibitory deficits in fibromyalgia patients. Pain, 2009, 145 (1-2), 18-23.
55. Jensen, K. B.; Kosek, E.; Petzke, F.; Carville, S.; Fransson, P.; Marcus, H.; Williams, S. C.; Choy, E.; Giesecke, T.; Mainguy, Y.; Gracely, R.; Ingvar, M. Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain, 2009, 144 (1-2), 95-100.
56. Vaeroy, H.; Helle, R.; Forre, O.; Kass, E.; Terenius, L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain, 1988, 32 (1), 21-26.
57. Russell, I. J.; Orr, M. D.; Littman, B.; Vipraio, G. A.; Alboukrek, D.; Michalek, J. E.; Lopez, Y.; MacKillip, F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum., 1994, 37 (11), 1593-1601.
58. Giovengo, S. L.; Russell, I. J.; Larson, A. A. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J. Rheumatol., 1999, 26 (7), 1564-1569.
59. Larsson, M. Ionotropic glutamate receptors in spinal nociceptive processing. Mol. Neurobiol., 2009, 40 (3), 260-288.
60. Pezet, S.; McMahon, S. B. Neurotrophins: mediators and modulators of pain. Annu. Rev. Neurosci., 2006, 29, 507-538.
61. Cheng, J. K.; Ji, R. R. Intracellular signaling in primary sensory neurons and persistent pain. Neurochem. Res., 2008, 33 (10), 1970-1978.
62. Staud, R.; Robinson, M. E.; Price, D. D. Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J. Pain, 2007, 8 (11), 893-901.
63. Staud, R.; Price, D. D.; Robinson, M. E.; Mauderli, A. P.; Vierck, C. J. Maintenance of windup of second pain requires less frequent stimulation in fibromyalgia patients compared to normal controls. Pain, 2004, 110 (3), 689-696.
64. Staud, R.; Bovee, C. E.; Robinson, M. E.; Price, D. D. Cutaneous C-fiber pain abnormalities of fibromyalgia patients are specifically related to temporal summation. Pain, 2008, 139 (2), 315-323.
65. Staud, R.; Craggs, J. G.; Perlstein, W. M.; Robinson, M. E.; Price, D. D., Brain activity associated with slow temporal summation of C-fiber evoked pain in fibromyalgia patients and healthy controls. Eur. J. Pain, 2008, 12 (8), 1078-1089.
66. Cook, D. B.; Lange, G.; Ciccone, D. S.; Liu, W. C.; Steffener, J.; Natelson, B. H. Functional imaging of pain in patients with primary fibromyalgia. J. Rheumatol., 2004, 31 (2), 364-378.
67. Harris, R. E.; Sundgren, P. C.; Pang, Y.; Hsu, M.; Petrou, M.; Kim, S. H.; McLean, S. A.; Gracely, R. H.; Clauw, D. J. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum/. 2008, 58 (3), 903-907.
68. Craig, A. D. How do you feel? Interoception: the sense of the physiological condition of the body. Nat. Rev. Neurosci., 2002, 3 (8), 655-566.
69. Harris, R. E.; Sundgren, P. C.; Craig, A. D.; Kirshenbaum, E.; Sen, A.; Napadow, V.; Clauw, D. J. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum., 2009, 60 (10), 3146-3152.
70. Burgmer, M.; Pogatzki-Zahn, E.; Gaubitz, M.; Wessoleck, E.; Heuft, G.; Pfleiderer, B. Altered brain activity during pain processing in fibromyalgia. Neuroimage, 2009, 44 (2), 502-508.
71. Ge, H. Y.; Nie, H.; Madeleine, P.; Danneskiold-Samsoe, B.; Graven-Nielsen, T.; Arendt-Nielsen, L. Contribution of the local and referred pain from active myofascial trigger points in fibromyalgia syndrome. Pain, 2009, 147 (1-3), 233-240.
72. Staud, R.; Nagel, S.; Robinson, M. E.; Price, D. D. Enhanced central pain processing of fibromyalgia patients is maintained by muscle afferent input: a randomized, double-blind, placebo-controlled study. Pain, 2009, 145 (1-2), 96-104.
73. Felix, F. H.; Fontenele, J. B. The OLETF rat as a model of central sensitization: possible relevance to the study of fibromyalgia and related diseases. J. Pharmacol. Sci., 2007, 105 (4), 372.
74. Miyasaka, K.; Funakoshi, A. Is the OLETF rat a good model of central sensitization? J. Pharmacol. Sci., 2007, 105 (4), 373.
75. Skyba, D. A.; Radhakrishnan, R.; Sluka, K. A. Characterization of a method for measuring primary hyperalgesia of deep somatic tissue. J. Pain, 2005, 6 (1), 41-47.
76. Tillu, D. V.; Gebhart, G. F.; Sluka, K. A. Descending facilitatory pathways from the RVM initiate and maintain bilateral hyperalgesia after muscle insult. Pain, 2008, 136 (3), 331-339.
77. Yokoyama, T.; Maeda, Y.; Audette, K. M.; Sluka, K. A. Pregabalin reduces muscle and cutaneous hyperalgesia in two models of chronic muscle pain in rats. J Pain 2007, 8 (5), 422-429.
78. Goldenberg, D. L.; Felson, D. T.; Dinerman, H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum., 1986, 29 (11), 1371-1377.
79. Yunus, M. B.; Masi, A. T.; Aldag, J. C. Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J. Rheumatol., 1989, 16 (4), 527-532.
80. Mease, P.; Arnold, L. M.; Bennett, R.; Boonen, A.; Buskila, D.; Carville, S.; Chappell, A.; Choy, E.; Clauw, D.; Dadabhoy, D.; Gendreau, M.; Goldenberg, D.; Littlejohn, G.; Martin, S.; Perera, P.; Russell, I. J.; Simon, L.; Spaeth, M.; Williams, D.; Crofford, L. Fibromyalgia syndrome. J. Rheumatol., 2007, 34 (6), 1415-1425.
81. Bian, F.; Li, Z.; Offord, J.; Davis, M. D.; McCormick, J.; Taylor, C. P.; Walker, L. C. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Res., 2006, 1075 (1), 68-80.
82. Bauer, C. S.; Nieto-Rostro, M.; Rahman, W.; Tran-Van-Minh, A.; Ferron, L.; Douglas, L.; Kadurin, I.; Sri Ranjan, Y.; Fernandez- Alacid, L.; Millar, N. S.; Dickenson, A. H.; Lujan, R.; Dolphin, A. C. The increased trafficking of the calcium channel subunit alpha2delta- 1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin. J. Neurosci., 2009, 29 (13), 4076-4088.
83. Field, M. J.; Cox, P. J.; Stott, E.; Melrose, H.; Offord, J.; Su, T. Z.; Bramwell, S.; Corradini, L.; England, S.; Winks, J.; Kinloch, R. A.; Hendrich, J.; Dolphin, A. C.; Webb, T.; Williams, D. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc. Natl. Acad. Sci. USA, 2006, 103 (46), 17537-17542.
84. Taylor, C. P.; Angelotti, T.; Fauman, E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2- delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res., 2007, 73 (2), 137-150.
85. Lyseng-Williamson, K. A.; Siddiqui, M. A. Pregabalin: a review of its use in fibromyalgia. Drugs, 2008, 68 (15), 2205-2223.
86. Frampton, J. E.; Foster, R. H. Pregabalin: in the treatment of postherpetic neuralgia. Drugs, 2005, 65 (1), 111-118. discussion 119-20.
87. Kubota, T.; Fang, J.; Meltzer, L. T.; Krueger, J. M. Pregabalin enhances nonrapid eye movement sleep. J. Pharmacol. Exp. Ther., 2001, 299 (3), 1095-1105.
88. Field, M. J.; Oles, R. J.; Singh, L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br. J. Pharmacol., 2001, 132 (1), 1-4.
89. Crofford, L. J.; Rowbotham, M. C.; Mease, P. J.; Russell, I. J.; Dworkin, R. H.; Corbin, A. E.; Young, J. P., Jr.; LaMoreaux, L. K.; Martin, S. A.; Sharma, U. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebocontrolled trial. Arthritis Rheum., 2005, 52 (4), 1264-1273.
90. Mease, P. J.; Russell, I. J.; Arnold, L. M.; Florian, H.; Young, J. P. Jr.; Martin, S. A.; Sharma, U., A randomized, double-blind, placebo- controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J. Rheumatol., 2008, 35 (3), 502-514.
91. Arnold, L. M.; Russell, I. J.; Diri, E. W.; Duan, W. R.; Young, J. P. Jr.; Sharma, U.; Martin, S. A.; Barrett, J. A.; Haig, G., A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J. Pain, 2008, 9 (9), 792-805.
92. Crofford, L. J.; Mease, P. J.; Simpson, S. L.; Young, J. P. Jr.; Martin, S. A.; Haig, G. M.; Sharma, U., Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain, 2008, 136 (3), 419-431.
93. Bymaster, F. P.; Lee, T. C.; Knadler, M. P.; Detke, M. J.; Iyengar, S. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr. Pharm. Des., 2005, 11 (12), 1475-1493.
94. Millan, M. J., Descending control of pain. Prog. Neurobiol., 2002, 66 (6), 355-474.
95. Bymaster, F. P.; Dreshfield-Ahmad, L. J.; Threlkeld, P. G.; Shaw, J. L.; Thompson, L.; Nelson, D. L.; Hemrick-Luecke, S. K.; Wong, D. T. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 2001, 25 (6), 871-880.
96. Iyengar, S.; Webster, A. A.; Hemrick-Luecke, S. K.; Xu, J. Y.; Simmons, R. M. Efficacy of duloxetine, a potent and balanced serotonin- norepinephrine reuptake inhibitor in persistent pain models in rats. J. Pharmacol. Exp. Ther., 2004, 311 (2), 576-584.
97. Curran, M. P. Duloxetine: in patients with fibromyalgia. Drugs, 2009, 69 (9), 1217-1227.
98. Arnold, L. M.; Lu, Y.; Crofford, L. J.; Wohlreich, M.; Detke, M. J.; Iyengar, S.; Goldstein, D. J. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum., 2004, 50 (9), 2974-2984.
99. Arnold, L. M.; Rosen, A.; Pritchett, Y. L.; D'Souza, D. N.; Goldstein, D. J.; Iyengar, S.; Wernicke, J. F. A randomized, doubleblind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain, 2005, 119 (1-3), 5-15.
100. Russell, I. J.; Mease, P. J.; Smith, T. R.; Kajdasz, D. K.; Wohlreich, M. M.; Detke, M. J.; Walker, D. J.; Chappell, A. S.; Arnold, L. M. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain, 2008, 136 (3), 432-444.
101. Chappell, A. S.; Bradley, L. A.; Wiltse, C.; Detke, M. J.; D'Souza, D. N.; Spaeth, M. A six-month double-blind, placebo-controlled, randomized trial of duloxetine for the treatment of fibromyalgia. Int. J. Gen. Med., 2008, 1, 91-102.
102. Mease, P. J.; Russell, I. J.; Kajdasz, D. K.; Wiltse, C. G.; Detke, M. J.; Wohlreich, M. M.; Walker, D. J.; Chappell, A. S. Long-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia. Semin. Arthritis Rheum., 2009, 39(6),454-64
103. Moret, C.; Charveron, M.; Finberg, J. P.; Couzinier, J. P.; Briley, M. Biochemical profile of midalcipran (F 2207), 1-phenyl-1- diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology, 1985, 24 (12), 1211-1219.
104. Vaishnavi, S. N.; Nemeroff, C. B.; Plott, S. J.; Rao, S. G.; Kranzler, J.; Owens, M. J. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol. Psychiatry, 2004, 55 (3), 320-322.
105. Puech, A.; Montgomery, S. A.; Prost, J. F.; Solles, A.; Briley, M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int. Clin. Psychopharmacol., 1997, 12 (2), 99-108.
106. Mochizucki, D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum. Psychopharmacol., 2004, 19 (Suppl 1), S15-19.
107. Chwieduk, C. M.; McCormack, P. L. Milnacipran: in fibromyalgia. Drugs, 2010, 70 (1), 99-108.
108. Gendreau, R. M.; Thorn, M. D.; Gendreau, J. F.; Kranzler, J. D.; Ribeiro, S.; Gracely, R. H.; Williams, D. A.; Mease, P. J.; McLean, S. A.; Clauw, D. J. Efficacy of milnacipran in patients with fibromyalgia. J. Rheumatol., 2005, 32 (10), 1975-1985.
109. Clauw, D. J.; Mease, P.; Palmer, R. H.; Gendreau, R. M.; Wang, Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple- dose clinical trial. Clin. Ther., 2008, 30 (11), 1988-2004.
110. Mease, P. J.; Clauw, D. J.; Gendreau, R. M.; Rao, S. G.; Kranzler, J.; Chen, W.; Palmer, R. H. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebocontrolled trial. J. Rheumatol., 2009, 36 (2), 398-409.
111. Mainguy, Y. Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. Hum. Psychopharmacol., 2009, 24 (Suppl 1), S19-23.
112. Tracey, I.; Mantyh, P. W. The cerebral signature for pain perception and its modulation. Neuron, 2007, 55 (3), 377-391.
113. Scharf, M. B.; Baumann, M.; Berkowitz, D. V. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J. Rheumatol., 2003, 30 (5), 1070-1074.
114. Russell, I. J.; Perkins, A. T.; Michalek, J. E. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum., 2009, 60 (1), 299-309.
115. Maitre, M.; Humbert, J. P.; Kemmel, V.; Aunis, D.; Andriamampandry, C. A mechanism for gamma-hydroxybutyrate (GHB) as a drug and a substance of abuse. Med. Sci., (Paris) 2005, 21 (3), 284-289.
116. Staud, R. Treatment of fibromyalgia and its symptoms. Exp. Opin Pharmacother., 2007, 8 (11), 1629-1642.
117. Schley, M.; Legler, A.; Skopp, G.; Schmelz, M.; Konrad, C.; Rukwied, R. Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief. Curr. Med. Res. Opin., 2006, 22 (7), 1269-1276.
118. Russo, E. B. Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuro. Endocrinol. Lett., 2008, 29 (2), 192-200.
119. Skrabek, R. Q.; Galimova, L.; Ethans, K.; Perry, D. Nabilone for the treatment of pain in fibromyalgia. J. Pain, 2008, 9 (2), 164-173.
120. Staud, R.; Koo, E. B. Are cannabinoids a new treatment option for pain in patients with fibromyalgia? Nat. Clin. Pract. Rheumatol., 2008, 4 (7), 348-349.